Natriumbikarbonat ”sad” (Sodium Hydrogen Carbonate)

Sodium bicarbonate is administered intravenously to address acid–base disturbances and related clinical conditions.

• Metabolic acidosis: restores normal systemic pH by buffering excess hydrogen ions.
• Cardiac arrest (ACLS): improves myocardial contractility and counteracts acidemia during resuscitation.
• Hyperkalemia: promotes intracellular shift of potassium, aiding in temporary reduction of serum potassium levels.
• Certain drug overdoses (e.g., tricyclic antidepressants): alkalinizes urine to enhance drug elimination.

• When infused, sodium bicarbonate dissociates into sodium and bicarbonate ions. The bicarbonate combines with hydrogen ions to form carbonic acid, which rapidly converts to water and carbon dioxide, thereby reducing hydrogen ion concentration and raising blood pH. This buffering action corrects metabolic acidosis and facilitates shifts of potassium into cells, supporting cardiac and neuromuscular function. The added sodium also contributes to extracellular fluid volume, which may require monitoring in patients with fluid restrictions.

Intravenous sodium bicarbonate may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Hypernatremia: elevated serum sodium levels.
• Metabolic alkalosis: excessive rise in blood pH.
• Fluid overload: increased intravascular volume.
• Hypokalemia: lowered serum potassium.
• Increased CO₂ production: may exacerbate respiratory distress.
• Local IV site irritation: pain or phlebitis at infusion site.

Serious or Rare Side Effects

• Severe alkalosis: can lead to seizures or cardiac arrhythmias.
• Pulmonary edema: accumulation of fluid in lungs.
• Paradoxical intracellular acidosis: worsening cellular acidosis despite systemic correction.
• Anaphylactic reaction: rare hypersensitivity with airway compromise.
• Severe hypernatremia: neurological symptoms such as confusion or coma.

Safe administration of sodium bicarbonate requires careful assessment and monitoring.

• Assess acid–base status: confirm metabolic acidosis before infusion.
• Monitor electrolytes: check serum sodium, potassium and bicarbonate levels regularly.
• Adjust infusion rate: titrate based on pH response and patient tolerance.
• Use caution in renal impairment: reduced excretion may increase risk of alkalosis.
• Avoid in severe pre‑existing alkalosis: may exacerbate condition.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Sodium bicarbonate can affect the pharmacokinetics or pharmacodynamics of several medicines.

Major Interactions (Avoid)

• Concomitant alkalinizing agents (e.g., calcium carbonate): may cause severe systemic alkalosis.
• Acid‑dependent drugs (e.g., aspirin, certain antifungals): reduced absorption and efficacy.
• Loop diuretics: enhanced electrolyte disturbances, especially hypokalemia.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: monitor potassium and renal function.
• Digoxin: risk of toxicity with altered potassium levels.
• NSAIDs: may increase risk of fluid overload and renal impairment.